The estimated Net Worth of Sabah Oney is at least $4.54 Million dollars as of 7 February 2020. Mr. Oney owns over 19,900 units of Alector stock worth over $3,334,464 and over the last 5 years he sold ALEC stock worth over $1,200,610. In addition, he makes $0 as Chief Business Officer at Alector.
Sabah has made over 7 trades of the Alector stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 19,900 units of ALEC stock worth $697,097 on 7 February 2020.
The largest trade he's ever made was selling 19,900 units of Alector stock on 7 February 2020 worth over $697,097. On average, Sabah trades about 7,778 units every 16 days since 2019. As of 7 February 2020 he still owns at least 573,918 units of Alector stock.
You can see the complete history of Mr. Oney stock trades at the bottom of the page.
Sabah Oney serves as Chief Business Officer of the Company. He has served as our Chief Business Officer since January 2018 and previously as our Vice President of Business Development and Operations since October 2016. From January 2016 until October 2016, Dr. Oney served as a consultant to a number of biotechnology companies. Dr. Oney previously served as Head of Global Sales and Business Development at Ariosa Diagnostics, Inc. (now a member of Roche Holding AG), a biotechnology company, from October 2015 to January 2016, and as Director of Business Development from September 2012 to October 2015. Dr. Oney received a Ph.D. in Genetics and Genomics from Duke University, an M.B.A. from Stanford University Graduate School of Business, and a B.S. in Genetics from the University of Kansas.
Sabah Oney is 37, he's been the Chief Business Officer of Alector since 2016. There are 19 older and no younger executives at Alector. The oldest executive at Alector, Inc. is Louis Lavigne, 72, who is the Lead Independent Director.
Sabah's mailing address filed with the SEC is C/O ALECTOR, INC., 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at Alector have traded over $148,873,269 worth of Alector stock and bought 20,000 units worth $500,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Advisors Llc Orbi Med Capit..., and Terrance Mcguire. On average, Alector executives and independent directors trade stock every 17 days with the average trade being worth of $438,922. The most recent stock trade was executed by Marc Grasso on 3 September 2024, trading 7,297 units of ALEC stock currently worth $35,609.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector executives and other stock owners filed with the SEC include: